COVID-19 and Central Nervous System Manifestations: A Systemic review on Therapeutic Outcome

Abstract

A novel caused the outbreak of coronavirus disease (COVID-19) has spread to Wuhan city of China and has become a global health issue and severe concern of the international community. Elderly patients with comorbidities, such as hypertension, diabetes mellitus, heart and lung disease, are more prone to COVID-19 Infection. COVID-19 and neurological disorders are two conditions with a well-documented association recently. Studies have shown that Infection with COVID-19 can alter the clinical spectrum of manifested neurological disorders and plays a vital role as long-term consequences in the development of diseases in the future. The SARS-CoV-2 virus reaches the brain either by an olfactory or by a hematogenous route pathway. Angiotensin-converting enzyme-2 (ACE-2) receptors, present in cerebral vessel endothelial cells of a cerebral vessel, are a potential viral entry point. Several cases of neurological disease have been identified recently, including Alzheimer's disease, Multiple sclerosis, and Parkinson's disease in COVID-19 patients, and a post-infectious immune-mediated inflammatory pathway has been held responsible for this. In this study, we try to explore the effect of COVID-19 on central nervous system damage and treatment of these manifestations. COVID-19 pandemic spreads to different parts of the world, the spectrum of neurological complications can expand further.